Roche to commercialize Hepatitis C drug in China with Ascletis
Key points
- Swiss drugmaker Roche Holding AG said it had teamed up with biotech firm Ascletis to develop and commercialize its investigative drug danoprevir in China for the treatment of the Hepatitis-C virus.
- Under the terms of the agreement, Ascletis will fund and be responsible for regulatory affairs and developing and manufacturing danoprevir in greater China, including Taiwan, Hong Kong and Macau.
- Ascletis will receive payments upon reaching certain development and commercial milestones from Roche.
- Ten million patients are infected annually with Hepatitis-C in China and there are no direct antiviral agents currently marketed to treat the disease, Ascletis said.
Swiss drugmaker Roche Holding AG said it had teamed up with biotech firm Ascletis to develop and commercialize its investigative drug danoprevir in China for the treatment of the Hepatitis-C virus.
Under the terms of the agreement, Ascletis will fund and be responsible for regulatory affairs and developing and manufacturing danoprevir in greater China, including Taiwan, Hong Kong and Macau.
Ascletis will receive payments upon reaching certain development and commercial milestones from Roche.
Ten million patients are infected annually with Hepatitis-C in China and there are no direct antiviral agents currently marketed to treat the disease, Ascletis said.
(Reporting by Caroline Copley)
###
Reuters - ZURICH
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.